Could you turn short-term pain into long-term gain with CSL shares?

CSL shares were the third most popular stock purchased by high-net-worth baby boomers in FY23.

| More on:
Two researchers discussing results of a study with each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares are down 0.37% to $267.08 apiece at lunchtime on Thursday.

The broader market is struggling with the S&P/ASX 200 Index (ASX: XJO) down 0.49% or 36 points.

This follows a 348-point drop or 0.98% for the Dow Jones Index (INDEXDJX: .DJI) overnight — the worst session since May, according to CNBC, following stronger-than-expected jobs data.

CSL shares have been languishing in 2023, down 5.22% in the year to date, while the ASX 200 is up 5.3%.

Should you be taking advantage of the weakness in this ASX 200 blue chip for long-term benefits?

CSL shares among top stocks bought by high-net-worths in FY23

You might have heard the term, 'follow the smart money'.

Well, if you believe that to be true, then CSL shares are an obvious buy right now.

According to data from trading platform Selfwealth Ltd (ASX: SWF), CSL shares were the third most popular stock purchased by high-net-worth baby boomer clients in FY23 (courtesy

The data canvassed the trading activity of clients with portfolios worth more than $1 million.

Over the past year, CSL shares have traded between a low of $255.87 and a high of $314.28.

More than a dozen experts backing CSL

As we recently reported, 12 top brokers are recommending CSL shares for investment right now.

A 13th expert, DNR Capital chief investment officer Jamie Nicol, added his support for CSL this week.

As we reported on Tuesday, Nicol said in a DNR video blog post:

What we are seeing in terms of opportunities is that uncertainty is driving some good quality companies to trade at discounts.

This environment has provided a rare opportunity to invest in good quality businesses that perhaps are getting disrupted through [a] hiccup in earnings, change in CEO, or a range of events…

Investors can pick up some of those businesses at really good discounts.

Rising and falling

On several occasions during FY23, the healthcare giant rose above the $300 threshold but failed to hold at that level.

This has given investors several opportunities to buy at depressed levels.

Nicol says CSL has some short-term challenges but "the longer term trajectory still looks very good".

Nicol said:

They've had a change of the CEO. 

They did have a downgrade to near term earnings which was all about the recovery and earnings post-COVID, and perhaps the recovery is taking a little bit longer than what they initially expected.

CSL downgraded its FY23 guidance in June due to foreign currency headwinds.

Still, the biotech estimates a 13% to 18% annual increase in its net profits after tax and amortisation (NPATA) in FY24. The guidance range is now approximately US$2.9 billion to US$3 billion.

Nicol added:

We always like to buy in periods of uncertainty, particularly when we are unclear on what the macro framework looks like.

We look for quality characteristics, good management, good businesses, good industry structure, competitive advantages, good ability to earn strong margins over the longer term because the market tends to gravitate back to those companies over time.

Citi and UBS have a buy rating on CSL shares and the highest 12-month price target of the bunch at $340.

Morgans says CSL shares are "poised to break out this year". The broker has an add rating and a $323 share price target.

Long-term gains produced by CSL shares

While past performance is no guarantee of future performance, CSL has an incredible history.

Since listing in 1994, the ASX 200 stalwart has gone up by 5,617%.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Bronwyn Allen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Exhausted young Caucasian woman lying on comfortable sofa in living room sleeping after hard-working day, tired millennial female fall asleep on couch at home, take nap or daydream, fatigue concept
Healthcare Shares

ResMed shares are in a two-month lull. Is this a chance to buy?

ResMed shares are still trading below the price targets of several brokers.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Healthcare Shares

Botanix shares jump on FDA approval and $70m capital raising

Investors are responding positively to some very big news.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now!

The little-known ASX healthcare stock has delivered eye-watering 12-month gains. But how?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Botanix Pharmaceuticals share price on watch amid FDA news and 'transformative event'

Big news has just been announced from this clinical dermatology company.

Read more »

Three health professionals at a hospital smile for the camera.
52-Week Highs

3 ASX healthcare shares smashing new 52-week highs today

The buying continues for these healthcare darlings.

Read more »

woman sitting at desk holding hand up in stop motion
Healthcare Shares

Guess which high-flying ASX All Ords stock was just halted ahead of a key FDA decision

The ASX All Ords stock is awaiting an important announcement from the US FDA.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Is the slashed Sonic Healthcare share price a 'buying opportunity'?

Is this stock a healthy opportunity?

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

ASX healthcare stock surges 11% on 'incredibly valuable' FDA news

Some big news is getting investors excited on Tuesday. What's happening?

Read more »